- Home
- ODD vs SRRK Comparison
ODD vs SRRK Comparison
Compare ODD & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- SRRK
- Stock Information
- Founded
- ODD 2018
- SRRK 2012
- Country
- ODD Israel
- SRRK United States
- Employees
- ODD N/A
- SRRK N/A
- Industry
- ODD
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ODD
- SRRK Health Care
- Exchange
- ODD Nasdaq
- SRRK Nasdaq
- Market Cap
- ODD 3.8B
- SRRK 3.2B
- IPO Year
- ODD 2023
- SRRK 2018
- Fundamental
- Price
- ODD $62.83
- SRRK $31.36
- Analyst Decision
- ODD Buy
- SRRK Strong Buy
- Analyst Count
- ODD 10
- SRRK 8
- Target Price
- ODD $72.10
- SRRK $44.29
- AVG Volume (30 Days)
- ODD 603.0K
- SRRK 1.8M
- Earning Date
- ODD 08-04-2025
- SRRK 08-06-2025
- Dividend Yield
- ODD N/A
- SRRK N/A
- EPS Growth
- ODD 25.95
- SRRK N/A
- EPS
- ODD 1.80
- SRRK N/A
- Revenue
- ODD $751,854,000.00
- SRRK N/A
- Revenue This Year
- ODD $25.45
- SRRK N/A
- Revenue Next Year
- ODD $20.24
- SRRK $3,116.02
- P/E Ratio
- ODD $34.53
- SRRK N/A
- Revenue Growth
- ODD 26.12
- SRRK N/A
- 52 Week Low
- ODD $32.71
- SRRK $6.76
- 52 Week High
- ODD $79.18
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- ODD 51.28
- SRRK 42.36
- Support Level
- ODD $58.40
- SRRK $32.16
- Resistance Level
- ODD $62.05
- SRRK $34.66
- Average True Range (ATR)
- ODD 1.82
- SRRK 2.05
- MACD
- ODD 0.67
- SRRK 0.02
- Stochastic Oscillator
- ODD 88.08
- SRRK 33.88
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.